Tachyon Therapeutics, Inc. (Tachyon), a research and development focused biotechnology company, and AbCellera (Nasdaq: ABCL), a technology company with a centralized operating system for next-generation antibody discovery, today announced a collaboration to facilitate the discovery and development of a therapeutic antibody targeting LEFTY1, a member of the transforming growth factor β (TGF-β) superfamily and validated extracellular drug target expressed in advanced cancers. Under the terms of the agreement, AbCellera is eligible to receive milestone payments and royalties on products that are derived from its antibody discovery platform. In addition, AbCellera has the option to invest in preclinical and clinical development in exchange for an increased share of product sales.